On Sept. 24, 2024, Hasten Biopharmaceutical Co., Ltd. and China Resources Pharmaceutical Commercial Group (Shanghai) Co., Ltd. signed a strategic agreement to deepen the comprehensive collaboration on further increasing branded drugs’ accessibility to Chinese patients.

Senior leadership team from Hasten, formed by Mr. Summer Xia(CEO of Hasten), Mr. Kevin Gu(EVP), Mr. Hanson Zheng(SVP), Mr. Jun Cheng(VP and Head of Finance), etc., was invited to pay a visit to China Resources Office in Shenzhen. Mr. Junyu Guo(Member of the Party Committee and Deputy General Manager of China Resources), Mr. Tao Lang(Member of the Party Committee and Deputy General Manager), Mr. Jiajun Yu(Vice General Manager of CR Pharma Commercial Shanghai Region), Mr. Shengkun Kang(International Business and National Distribution Manager) received Hasten team and witnessed the conclusion of the strategic cooperation.

Summer Xia, CEO of Hasten, said, “Hasten and China Resources (Shanghai) had built a trustable relationship since both parties signed the first contract on the 2023 CIIE. Today's reunion is a demonstration for the deep cooperation and high level of trust between both sides while pursuing common development. This is not only a complement in business, but also a fit in value and vision. Through this strategic cooperation, we will further integrate the strengths of both sides, jointly promote innovation and development in the field of healthcare, and benefit a wider range of patients.

Mr. Kevin Gu, Executive Vice President of Hasten, said: “The prior innovative strategic cooperation between Hasten and China Resources (Shanghai) has achieved fruitful results in the past. This deep strategic cooperation will enable both sides to achieve comprehensive cooperation in omni-channel agent, extensive market cultivation and third-party logistics distribution in the fields of chronic diseases and critical illnesses. Through the efforts of both parties, we will benefit more patients and create significant social health value jointly.